Menu Search
Equities

Medistim ASA

MD1:STU

Medistim ASA

Actions
  • Price (EUR)16.20
  • Today's Change0.150 / 0.93%
  • Shares traded0.00
  • 1 Year change-29.26%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistim’s activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.

  • Revenue in NOK (TTM)530.89m
  • Net income in NOK102.54m
  • Incorporated1995
  • Employees152.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.